CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma
- PMID: 31981231
- DOI: "V体育官网入口" 10.1002/eji.201948457
CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma
V体育安卓版 - Abstract
Unlike hematological malignancies, solid tumors have proved to be less susceptible to chimeric antigen receptor (CAR)-T cell therapy, which is partially caused by reduced accumulation of therapeutic T cells in tumor site VSports手机版. Since efficient trafficking is the precondition and pivotal step for infused CAR-T cells to exhibit their anti-tumor function, strategies are highly needed to improve the trafficking ability of CAR-T cells for solid tumor treatment. Here, based on natural lymphocyte chemotaxis theory and characteristics of solid tumor microenvironments, we explored the possibility of enhancing CAR-T cell trafficking by using chemokine receptors. Our study found that compared with other chemokines, several CXCR2 ligands showed relatively high expression level in human hepatocellular carcinoma tumor tissues and cell lines. However, both human peripheral T cells and hepatocellular carcinoma tumor infiltrating T cells lacked expression of CXCR2. CXCR2-expressing CAR-T cells exhibited identical cytotoxicity but displayed significantly increased migration ability in vitro. In a xenograft tumor model, we found that expressing CXCR2 in CAR-T cells could significantly accelerate in vivo trafficking and tumor-specific accumulation, and improve anti-tumor effect of these cells. .
Keywords: CAR-T; CXCR2; Chemokine; Immunotherapy. V体育安卓版.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim V体育ios版. .
"VSports" References
-
- Guo, Y., Wang, Y. and Han, W., Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects. J. Immunol. Res. 2016. 2016: 3850839.
-
- Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E. et al., A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006. 12: 6106-6115.
-
- Knochelmann, H. M., Smith, A. S., Dwyer, C. J., Wyatt, M. M., Mehrotra, S. and Paulos, C. M., CAR T cells in solid tumors: blueprints for building effective therapies. Front Immunol 2018. 9: 1740.
-
- Hughes, C. E. and Nibbs, R. J. B., A guide to chemokines and their receptors. FEBS J. 2018. 285: 2944-2971.
-
- Beck, L. A., Tancowny, B., Brummet, M. E., Asaki, S. Y., Curry, S. L., Penno, M. B., Foster, M. et al., Functional analysis of the chemokine receptor CCR3 on airway epithelial cells. J. Immunol. 2006. 177: 3344-3354.
Publication types
- "VSports app下载" Actions
MeSH terms
- Actions (V体育2025版)
- Actions (V体育官网入口)
- "V体育安卓版" Actions
- VSports在线直播 - Actions
- "VSports最新版本" Actions
- Actions (VSports在线直播)
- Actions (VSports在线直播)
- Actions (V体育2025版)
- V体育2025版 - Actions
- VSports app下载 - Actions
- "V体育平台登录" Actions
- Actions (VSports app下载)
- "V体育2025版" Actions
- "V体育平台登录" Actions
- VSports在线直播 - Actions
Substances
- Actions (VSports注册入口)
- "V体育安卓版" Actions
- "VSports注册入口" Actions
- V体育官网入口 - Actions
- V体育ios版 - Actions
- V体育ios版 - Actions
- "VSports手机版" Actions
"V体育2025版" Grants and funding
- 31821003/National Natural Science Foundation of China/International
- 31930039/National Natural Science Foundation of China/International
- 81630058/National Natural Science Foundation of China/International
- 91942303/National Natural Science Foundation of China/International
- 81971469/National Natural Science Foundation of China/International
LinkOut - more resources
V体育安卓版 - Full Text Sources
Other Literature Sources
Medical